Affymetrix, Partners HealthCare collaborate
This article was originally published in The Gray Sheet
Diagnostics firm inks three-year translational research agreement with Partners managed care organization to develop microassay-based diagnostics for newborn hearing loss, autism, hypertrophic cardiomyopathy and other conditions. Partners is an integrated healthcare delivery system comprising Brigham & Women's Hospital and Massachusetts General in Boston. Partners' researchers at Harvard Medical School will create and validate the microarray tests in Clinical Laboratory Improvement Amendments-regulated labs. Affymetrix' Translational Medicine Program develops molecular signatures to create custom-designed microarray products that help researchers diagnose and tailor treatments for individual patients...
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.